Prof. Dr. dr. Teguh Santoso, M.D., Sp. PD-KKV, Sp. JP, Ph.D., FACC, FESC from Medistra Hospital Jakarta who participated in EuroPCR as one of the symposium speakers said that Bioadaptor has unique capabilities unlike traditional drug-eluting stents.
“At Medistra hospital, where I practice, Bioadaptor is my preferred choice for all types of percutaneous coronary intervention (PCI) cases, even those with highly challenging anatomical features. The Bioadaptor stands out for its unique ability to restore vessel physiology, a feature that is limited in Drug Eluting Stents (DES).”
“The implantation techniques, tips, and tricks for Bioadaptor are similar to those of best-in-class DES, its performance in terms of deliverability, conformability, radial strength, side branch access, and expandability is comparable to DES. Based on my experience, this remarkable stent is highly promising for treating all kinds of PCI cases.” explained Prof. Teguh Santoso.
Late-breaker presentation details:
Title: “12-Month primary endpoint outcomes of the Bioadaptor RCT”
Principal Investigator: Shigeru Saito, M.D., Director of the Cardiology and Catheterization Laboratory at Shonan Kamakura General Hospital in Kanagawa, Japan
Date: Wednesday, May 17, 2023
Time: 14:45 CEST
Location: Room Maillot
Symposium details:
Title: “Restoring vessel physiology and function with DynamX Bioadaptor – the holy grail of PCI”
Anchorperson: Antonio Colombo, M.D.
Spokesperson: Johan Bennett, M.D.
Discussants: Shigeru Saito, M.D., Holger Nef, M.D., Stefan Verheye, M.D., Teguh Santoso, M.D.
Date: Wednesday, May 17, 2023
Time: 13:30 CEST
Location: Room 252B
About the Bioadaptor RCT Trial
The Bioadaptor RCT is an international, single-blinded, randomized controlled (1:1) trial compared a sirolimus-eluting Bioadaptor with a contemporary zotarolimus-eluting stent, a drug-eluting stent, in 445 patients. An imaging subset of 100 patients had angiographic and intravascular ultrasound assessments, and 20 patients additionally had optical coherence tomography. Data collection will continue through five years.
